English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Human glioma facilitates an impaired anti-tumor immunity response, including defects in circulation of T lymphocytes. The level of CD8 +  T-cell activation acts as an immune regulator associated with disease progression. However, little is known about the characteristics of peripheral and tumor-infiltrating CD8 +  T cells in patients with glioma. In this study, we examined the level of CD8 +  T-cell activation in a group of 143 patients with glioma and determined that peripheral CD3 +  T cells decreased in accordance with disease severity. The patients' peripheral CD8 +  T-cell populations were similar to that of healthy donors, and a small amount of CD8 +  tumor-infiltrating lymphocytes was identified in glioma tissues. An increase in activated CD8 +  T cells, characterized as CD38 + HLA-DR + , and their association with disease progression were identified in the patients' peripheral blood and glioma, and shown to display enriched CCR5 +  and TNFR2 +  expression levels.  Ex vivo  examination of CD38 + HLA-DR + CD8 +  T cells indicated that this subset of cells displayed stronger secretion of IFN-γ and IL-2 before and after a 6-h stimulation with phorbol 12-myristate 13-acetate (PMA) and ionomycin (ION) relative to healthy CD38 + HLA-DR + CD8 +  T cells, indicating the functional feasibility of CD38 + HLA-DR + CD8 +  T cells. Higher CCL5 protein and mRNA levels were identified in glioma tissues, which was consistent with the immunohistochemistry results revealing both CCL5 and CD38 + HLA-DR + CD8 +  T cell expression. Patients' CCR5 + CD38 + HLA-DR + CD8 +  T cells were further validated and shown to display increases in CD45RA + CCR7 −  and T-bet +  accompanied by substantial CD107-a, IFN-γ, and Granzyme B levels in response to glioma cells.

Functional Change of Effector Tumor-Infiltrating CCR5+CD38+HLA-DR+CD8+ T Cells in Glioma Microenvironment